Gender	Male
E-mail	william.oh@mssm.edu
Education and Training	MD, New York University School of Medicine
Awards	2008 - 2009 America’s Top Doctors for Cancer (Castle Connolly)
	2007 - 2008 Brigham/Harvard Business School Physician Leadership Program
	2005 Boston Magazine “Top Doctors”
	2004 - 2009 Who’s Who in America
	2003 - 2009 Best Doctors in America
	2003 Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention
	2002 - 2003 Dunkin Donuts Rising Stars Award
	1997 ASCO/AACR Methods in Clinical Cancer Research Workshop
	1992 Prize in Internal Medicine, NYU School of Medicine
	1992 Alpha Omega Alpha

William K. Oh, M.D. is the Chief of the Division of Hematology and Medical Oncology; Professor of Medicine and Urology; and Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics at the Mount Sinai School of Medicine and Associate Director for Clinical Research, The Tisch Cancer Institute.

Clinical Interests: Management of genitourinary malignancies, including prostate, renal, bladder, adrenocortical and testicular cancers.  
 
Research Interests: Dr. Oh's research interests include exploring the role of chemotherapy in both hormone-refractory (HRPC) and localized high-risk prostate cancer.  In collaboration with laboratory-based colleagues, we are assessing changes in the expression of tissue and serum biomarkers due to chemotherapy.  Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer.  

Another major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh's recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.  

Education and Training	MD, New York University School of Medicine

Oh WK Md, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright R, Tormey L, Talcott J, Rubin M, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks JC. Development of an integrated prostate cancer information system: Prostate CRIS. Clin. Genitourin. Cancer 2006; 5(1): 61-66.

Oh WK Md, Sher DJ, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008; 68(14): 1592-1598.

Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK Md. Absence of a relationship between steroid hormone levels and tumor grade in a prospective cohort of prostate cancer. Urology 2009 Feb; 73(2): 356-361.

Choueiri TC, Xie W, D’Amico AV, Ross RW, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK Md. Time to PSA nadir independently predicts overall survival in metastatic hormone sensitive prostate cancer patients treated with androgen deprivation therapy. Cancer 2009 Mar; 115(5): 981-987.

Oh WK Md, Chan JM, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. Plasma selenium, manganese superoxide dismutase (SOD2) and intermediate or high risk prostate cancer. J. Clin. Oncol. ;.

Pomerantz MM, Beckwith CA, Regan MM, Stacia K, Wyman SK, Petrovics G, Chen Y, Dorota J, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer ML, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK Md, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Research 2009 Jul; 69(13): 5568-5574.

Regan MM, O’Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK Md. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of 7 prospective clinical trials. Ann. Oncol.;.

Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy G, Antras L, Jayawant SS, Chen K, Wang ST, Luka A, Neary NP, McDermott D, Oh WK Md. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety, and treatment patterns in clinical practice based on medical chart review. BJU Int.;.

Oh WK Md, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before luteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? . Urology;.

Rosenberg J, Oh WK Md. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? . Nat. Clin. Pract. Oncol. 2008 Dec.; 5(12): 650-651.